The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
Article Details
- CitationCopy to clipboard
Choi SE, Pflum MK
The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
Bioorg Med Chem Lett. 2012 Dec 1;22(23):7084-6. doi: 10.1016/j.bmcl.2012.09.093. Epub 2012 Oct 2.
- PubMed ID
- 23089527 [ View in PubMed]
- Abstract
Suberoylanilide hydroxamic acid (SAHA, Vorinostat), the first FDA-approved histone deacetylase (HDAC) inhibitor drug, was modified at the C6 position to study the structural requirements for high potency and selectivity. Substituents on the C6 position only modestly influenced inhibitor potency, with poorer activity observed as substituent size increased. Interestingly, C6 substituents also modestly influenced selectivity compared to the parent compound, SAHA. This systematic study documenting the influence of substituents on the SAHA linker region will aid development of anti-cancer drugs targeting HDAC proteins.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Vorinostat Histone deacetylase 1 IC 50 (nM) 96 N/A N/A Details Vorinostat Histone deacetylase 3 IC 50 (nM) 136 N/A N/A Details Vorinostat Histone deacetylase 6 IC 50 (nM) 74 N/A N/A Details